

Christopher P Crum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1315028/publications.pdf>

Version: 2024-02-01

140
papers

18,571
citations

16411

64
h-index

14702

127
g-index

142
all docs

142
docs citations

142
times ranked

15951
citing authors

#	ARTICLE	IF	CITATIONS
1	p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. <i>Nature</i> , 1999, 398, 714-718.	13.7	2,082
2	Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship. <i>American Journal of Surgical Pathology</i> , 2007, 31, 161-169.	2.1	980
3	The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome. <i>American Journal of Surgical Pathology</i> , 2006, 30, 230-236.	2.1	797
4	p63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia. <i>Cell</i> , 2007, 129, 523-536.	13.5	783
5	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014, 506, 371-375.	13.7	708
6	Distal Airway Stem Cells Yield Alveoli In Vitro and during Lung Regeneration following H1N1 Influenza Infection. <i>Cell</i> , 2011, 147, 525-538.	13.5	510
7	Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. <i>Cancer Cell</i> , 2013, 24, 751-765.	7.7	488
8	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. <i>Cancer Research</i> , 2005, 65, 2162-2169.	0.4	484
9	p63 protects the female germ line during meiotic arrest. <i>Nature</i> , 2006, 444, 624-628.	13.7	479
10	Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2007, 25, 3985-3990.	0.8	453
11	p63+Krt5+ distal airway stem cells are essential for lung regeneration. <i>Nature</i> , 2015, 517, 616-620.	13.7	433
12	The distal fallopian tube: a new model for pelvic serous carcinogenesis. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 3-9.	0.9	425
13	Human Papillomavirus Type 16 and Early Cervical Neoplasia. <i>New England Journal of Medicine</i> , 1984, 310, 880-883.	13.9	416
14	Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia. <i>American Journal of Surgical Pathology</i> , 2001, 25, 884-891.	2.1	405
15	New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. <i>Journal of Clinical Oncology</i> , 2008, 26, 5284-5293.	0.8	362
16	A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10516-10521.	3.3	350
17	Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2008, 26, 4160-4165.	0.8	317
18	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. <i>Cancer Discovery</i> , 2018, 8, 1404-1421.	7.7	311

#	ARTICLE	IF	CITATIONS
19	Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer. <i>Clinical Medicine and Research</i> , 2007, 5, 35-44.	0.4	301
20	Residual Embryonic Cells as Precursors of a Barrett's-like Metaplasia. <i>Cell</i> , 2011, 145, 1023-1035.	13.5	292
21	Serous Carcinogenesis in the Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 1-9.	0.9	275
22	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 109, 168-173.	0.6	268
23	Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. <i>American Journal of Pathology</i> , 2002, 161, 1199-1206.	1.9	240
24	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S118-29.	1.0	194
25	p63 in Epithelial Survival, Germ Cell Surveillance, and Neoplasia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2010, 5, 349-371.	9.6	191
26	Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. , 2000, 190, 462-469.		171
27	Cloning and variation of ground state intestinal stem cells. <i>Nature</i> , 2015, 522, 173-178.	13.7	156
28	Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: A study of 250 cases. <i>Human Pathology</i> , 2001, 32, 479-486.	1.1	153
29	Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 916-926.	0.7	152
30	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. <i>Nature Communications</i> , 2015, 6, 7419.	5.8	149
31	Advances in the Recognition of Tubal Intraepithelial Carcinoma. <i>Advances in Anatomic Pathology</i> , 2006, 13, 1-7.	2.4	144
32	Stratified Mucin-Producing Intraepithelial Lesions of the Cervix. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1414-1419.	2.1	143
33	Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. <i>Molecular Oncology</i> , 2009, 3, 165-170.	2.1	143
34	Expression of the p53 Homologue p63 in Early Cervical Neoplasia. <i>Gynecologic Oncology</i> , 2001, 80, 24-29.	0.6	131
35	Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. <i>Journal of Pathology</i> , 2010, 222, 110-116.	2.1	129
36	SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. <i>Modern Pathology</i> , 2018, 31, 1442-1456.	2.9	128

#	ARTICLE	IF	CITATIONS
37	Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass. American Journal of Surgical Pathology, 2009, 33, 376-383.	2.1	126
38	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	3.4	121
39	p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Human Pathology, 2004, 35, 1477-1483.	1.1	117
40	Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. Modern Pathology, 2010, 23, 404-412.	2.9	115
41	BMP4-directed trophoblast differentiation of human embryonic stem cells is mediated through a β -Np63+ cytotrophoblast stem cell state. Development (Cambridge), 2013, 140, 3965-3976.	1.2	111
42	Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. American Journal of Surgical Pathology, 2018, 42, 227-233.	2.1	110
43	High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Modern Pathology, 2010, 23, 1316-1324.	2.9	109
44	p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female Urogenital Tract. American Journal of Pathology, 2002, 161, 1111-1117.	1.9	106
45	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. ELife, 2017, 6, .	2.8	106
46	Evidence for a Dualistic Model of High-grade Serous Carcinoma. American Journal of Surgical Pathology, 2015, 39, 287-293.	2.1	96
47	STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis. Frontiers in Bioscience - Elite, 2011, E3, 625-634.	0.9	90
48	Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecologic Oncology, 2016, 142, 293-298.	0.6	87
49	Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance. International Journal of Gynecological Pathology, 2009, 28, 308-315.	0.9	86
50	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Research, 2021, 81, 158-173.	0.4	85
51	Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk. Modern Pathology, 2015, 28, 994-1000.	2.9	84
52	Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and its Implications. International Journal of Gynecological Pathology, 2010, 29, 310-314.	0.9	83
53	A novel blueprint for "top down" differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. Journal of Pathology, 2013, 229, 460-468.	2.1	81
54	Allelic Imbalance in Lichen Sclerosus, Hyperplasia, and Intraepithelial Neoplasia of the Vulva. Gynecologic Oncology, 2000, 77, 171-176.	0.6	78

#	ARTICLE	IF	CITATIONS
55	A unifying concept of trophoblastic differentiation and malignancy defined by biomarker expression. <i>Human Pathology</i> , 2007, 38, 1003-1013.	1.1	78
56	Risk factors for a serous cancer precursor (â€œp53 signatureâ€œ) in women with inherited BRCA mutations. <i>Gynecologic Oncology</i> , 2008, 111, 226-232.	0.6	77
57	Serous tubal intraepithelial neoplasia: the concept and its application. <i>Modern Pathology</i> , 2017, 30, 710-721.	2.9	77
58	The fallopian tube, â€œprecursor escapeâ€œand narrowing the knowledge gap to the origins of high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 152, 426-433.	0.6	77
59	Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium: A Study with the p53 Homologue p63. <i>Gynecologic Oncology</i> , 2001, 80, 30-36.	0.6	74
60	Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2014, 132, 280-286.	0.6	74
61	First International Consensus Report on Adnexal Masses: Management Recommendations. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 849-863.	0.8	72
62	Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. <i>Modern Pathology</i> , 2017, 30, 448-458.	2.9	72
63	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	1.0	70
64	Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia. <i>Human Pathology</i> , 2004, 35, 1014-1021.	1.1	69
65	Through the glass darkly: intraepithelial neoplasia, topâ€œdown differentiation, and the road to ovarian cancer. <i>Journal of Pathology</i> , 2013, 231, 402-412.	2.1	68
66	<i>In vitro</i> and <i>in vivo</i> correlates of physiological and neoplastic human Fallopian tube stem cells. <i>Journal of Pathology</i> , 2016, 238, 519-530.	2.1	68
67	The Oviduct and Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 24-35.	0.6	65
68	Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. <i>Modern Pathology</i> , 2009, 22, 345-350.	2.9	61
69	Cervical Squamocolumnar Junctionâ€œspecific Markers Define Distinct, Clinically Relevant Subsets of Low-grade Squamous Intraepithelial Lesions. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1311-1318.	2.1	60
70	Fallopian Tube Correlates of Ovarian Serous Borderline Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1759-1765.	2.1	59
71	Carcinogenic HPV infection in the cervical squamoâ€œcolumnar junction. <i>Journal of Pathology</i> , 2015, 236, 265-271.	2.1	59
72	Contemporary Theories of Cervical Carcinogenesis: The Virus, the Host, and the Stem Cell. <i>Modern Pathology</i> , 2000, 13, 243-251.	2.9	58

#	ARTICLE	IF	CITATIONS
73	Mutational spectrum of Barrett's stem cells suggests paths to initiation of a precancerous lesion. <i>Nature Communications</i> , 2016, 7, 10380.	5.8	57
74	Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. <i>Journal of Pathology</i> , 2018, 246, 344-351.	2.1	55
75	Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. <i>Human Pathology</i> , 2005, 36, 154-161.	1.1	49
76	BRCA, the Oviduct, and the Space and Time Continuum of Pelvic Serous Carcinogenesis. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S29-S34.	1.2	49
77	PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. <i>Modern Pathology</i> , 2012, 25, 449-455.	2.9	47
78	Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 104-111.	0.6	47
79	Molecular changes in endometriosis-associated ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1831-1842.	1.3	44
80	Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. <i>Modern Pathology</i> , 2009, 22, 985-988.	2.9	43
81	Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. <i>PLoS ONE</i> , 2013, 8, e80314.	1.1	43
82	Allelic Loss in Human Papillomavirus-Positive and -Negative Vulvar Squamous Cell Carcinomas. <i>American Journal of Pathology</i> , 1999, 154, 1009-1015.	1.9	42
83	Cellular Origin of Barrett's Esophagus: Controversy and Therapeutic Implications. <i>Gastroenterology</i> , 2012, 142, 1424-1430.	0.6	42
84	The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. <i>Journal of Pathology</i> , 2010, 220, 17-23.	2.1	41
85	The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. <i>Modern Pathology</i> , 2011, 24, 152-156.	2.9	41
86	Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. <i>International Journal of Cancer</i> , 2015, 137, 776-783.	2.3	39
87	Surgical prevention strategies in ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 166-175.	0.6	38
88	Symposium Part 1: Should the Bethesda System Terminology be Used in Diagnostic Surgical Pathology?: Point. <i>International Journal of Gynecological Pathology</i> , 2003, 22, 5-12.	0.9	36
89	Frequency of incidental serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. <i>Gynecologic Oncology</i> , 2017, 146, 69-73.	0.6	34
90	Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. <i>Modern Pathology</i> , 2016, 29, 893-903.	2.9	33

#	ARTICLE	IF	CITATIONS
91	Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. <i>Journal of Pathology</i> , 2017, 241, 522-533.	2.1	32
92	Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. <i>Cancers</i> , 2018, 10, 468.	1.7	31
93	The <sc>PAX2</sc>-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. <i>Journal of Pathology</i> , 2014, 234, 478-487.	2.1	30
94	A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. <i>British Journal of Cancer</i> , 2018, 118, 1302-1312.	2.9	30
95	Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. <i>International Journal of Cancer</i> , 2015, 136, 1043-1052.	2.3	29
96	Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis. <i>Viruses</i> , 2017, 9, 85.	1.5	29
97	Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. <i>Diagnostic Histopathology</i> , 2008, 14, 352-365.	0.2	28
98	Hertig and Beyond: A Systematic and Practical Approach to the Endometrial Biopsy. <i>Advances in Anatomic Pathology</i> , 2003, 10, 301-318.	2.4	27
99	Dynamics of Human Papillomavirus Infection between Biopsy and Excision of Cervical Intraepithelial Neoplasia: Results from the ZYC101a Protocol. <i>Journal of Infectious Diseases</i> , 2004, 189, 1348-1354.	1.9	26
100	p16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary. <i>Modern Pathology</i> , 2016, 29, 1501-1510.	2.9	26
101	Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. <i>Gynecologic Oncology</i> , 2009, 115, 108-111.	0.6	24
102	Koilocytotic atypia in papanicolaou smears. , 1997, 81, 10-15.		22
103	Human Papillomavirus Type 16 Infection. <i>International Journal of Gynecological Pathology</i> , 1986, 5, 287-296.	0.9	19
104	Cytologic correlates of papillary immature metaplasia (immature condyloma) of the cervix. <i>Diagnostic Cytopathology</i> , 1998, 18, 416-421.	0.5	18
105	Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. <i>International Journal of Cancer</i> , 2013, 133, 730-739.	2.3	18
106	Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles. <i>Gynecologic Oncology</i> , 2013, 128, 488-492.	0.6	16
107	Squamocolumnar junction ablation—tying up loose ends?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 378-380.	12.5	16
108	MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread. <i>Oncogene</i> , 2020, 39, 4045-4060.	2.6	13

#	ARTICLE	IF	CITATIONS
109	Vaccines for Cervical Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 368-376.	1.0	12
110	Laboratory Management of Cervical Intraepithelial Neoplasia. <i>Advances in Anatomic Pathology</i> , 2013, 20, 86-94.	2.4	12
111	Frontiers in the Pathology and Pathogenesis of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 915-928.	0.9	12
112	Bringing the p53 signature into focus. <i>Cancer</i> , 2010, 116, 5119-5121.	2.0	11
113	Cervical Squamous Neoplasia. , 2018, , 298-374.		11
114	The Cellular Origin of Barrett's Esophagus and Its Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1123, 55-69.	0.8	11
115	Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. <i>Modern Pathology</i> , 2021, 34, 613-626.	2.9	11
116	Interobserver reproducibility of the diagnosis of differentiated exophytic vulvar intraepithelial lesion (DEVIL) and the distinction from its mimics. <i>Histopathology</i> , 2021, 79, 957-965.	1.6	11
117	Salpingectomy as a Potential Ovarian Cancer Risk-Reducing Procedure. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju490-dju490.	3.0	10
118	Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. <i>Journal of Global Oncology</i> , 2017, 3, 227-234.	0.5	10
119	Origin of clear cell carcinoma: nature or nurture?. <i>Journal of Pathology</i> , 2018, 244, 131-134.	2.1	10
120	Digital quantification of precursor frequency in the fallopian tube and its significance. <i>Modern Pathology</i> , 2012, 25, 1654-1661.	2.9	8
121	Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 443-448.	0.9	8
122	Differential Expression of p-ERM, a Marker of Cell Polarity, in Benign and Neoplastic Oviductal Epithelium. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 345-352.	0.9	7
123	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	0.7	7
124	Preventing Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 198-199.	0.8	7
125	Evidence for a Novel Endometrioid Carcinogenic Sequence in the Fallopian Tube With Unique Beta-Catenin Expression. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 163-169.	0.9	6
126	Ovarian cancer survival by tumor dominance, a surrogate for site of origin. <i>Cancer Causes and Control</i> , 2015, 26, 601-608.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Koilocytotic atypia in papanicolaou smears. , 1997, 81, 10.		4
128	Response to Gilks et al. Modern Pathology, 2011, 24, 1282-1283.	2.9	3
129	Human papillomaviruses. Applications, caveats and prevention. Journal of reproductive medicine, The, 2002, 47, 519-28; discussion 528-9.	0.2	3
130	Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers, 2021, 13, 3218.	1.7	2
131	Molecular catastrophe, the peritoneal cavity and ovarian cancer prevention. Journal of Pathology, 2022, , .	2.1	2
132	The Fallopian Tube and Broad Ligament. , 2018, , 716-760.		1
133	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2018, , 865-948.		1
134	The Fallopian Tube and Broad Ligament. , 2011, , 640-678.		1
135	Peritoneal and tubal serous carcinoma. , 0, , 111-120.		0
136	Response to "Two major pathways of recurrent high-grade squamous intraepithelial lesions of the cervix". International Journal of Cancer, 2015, 137, 2522-2523.	2.3	0
137	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0
138	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1"AKT"p53 Interactions. Cancers, 2021, 13, 2195.	1.7	0
139	A multi-step model of pelvic serous carcinogenesis that originates in the distal fallopian tube from a novel precursor lesion.. FASEB Journal, 2007, 21, A77.	0.2	0
140	Prognostic importance of p16 status for women with vulvar squamous cell carcinoma (SCC) treated with radiotherapy.. Journal of Clinical Oncology, 2017, 35, 5599-5599.	0.8	0